Concentration-Dependent Dual Effects of Ciprofloxacin on SB-590885-Resistant BRAF A375 Melanoma Cells.

BRAF inhibitors (BRAFi) have been applied to treat melanoma harboring V600E mutations. Several studies showed that BRAFi-resistant melanomas are dependent on mitochondrial biogenesis. Therefore, the present study aimed to investigate the influence of ciprofloxacin (CIP), a mitochondria-targeting antibiotic, on SB-590885-resistant BRAF A375 melanoma (A375/SB) cells.